Treatment of progressive supranuclear palsy and corticobasal degeneration

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Movement Disorders

• Publication date

  2005-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/mds.20545PMID 16092096
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nefiracetam enhances acetylcholine outflow from the frontal cortex: in vivo microdialysis study in the rat

  2005cited by this paper
• The influence of taipoxin on cholinergic synapses in the electric organ ofTorpedo Marmorata

  2005cited by this paper
• Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia

  2003cited by this paper
• Double‐blind, placebo‐controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism

  2003cited by this paper
• Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy Brain Bank

  2003cited by this paper
• Zolpidem in progressive supranuclear palsy

  2002cited by this paper
• Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study

  2002cited by this paper
• Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy.

  2002cited by this paper
• The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.

  2002cited by this paper
• Progressive supranuclear palsy diagnosis and confounding features: Report on 16 autopsied cases

  2002cited by this paper
• Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy

  2001cited by this paper
• Donepezil in the treatment of progressive supranuclear palsy

  2001cited by this paper
• Treatment of dystonic clenched fist with botulinum toxin

  2001cited by this paper
• Botulinum toxin A as treatment for drooling saliva in PD

  2000cited by this paper
• Levodopa‐induced dyskinesias in autopsy‐proven cortical‐basal ganglionic degeneration

  2000cited by this paper
• Valproate-induced hyperammonemic encephalopathy in the presence of topiramate

  2000cited by this paper
• Pramipexole in progressive supranuclear palsy

  1999cited by this paper
• Zolpidem in progressive supranuclear palsy.

  1999cited by this paper
• Pharmacological therapy in progressive supranuclear palsy.

  1998cited by this paper
• Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy

  1998cited by this paper
• Clinical presentation and pharmacological therapy in corticobasal degeneration.

  1998cited by this paper
• Result of long-term administration of L-threo-3,4-dihydroxyphenylserine in patients with pure akinesia as an early symptom of progressive supranuclear palsy.

  1997cited by this paper
• Aniracetam for treatment of patients with progressive supranuclear palsy.

  1997cited by this paper
• Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening.

  1996cited by this paper
• Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)

  1996cited by this paper
• Limited usefulness of electroconvulsive therapy in progressive supranuclear palsy

  1996cited by this paper
• Innervation of propatagial musculature in a flying squirrel, Glaucomys volans (Rodentia, Sciuridae).

  1996cited by this paper
• Progressive supranuclear palsy: a clinicopathological study of 21 cases

  1996cited by this paper
• Botulinum toxin A for spasticity, muscle spasms, and rigidity

  1995cited by this paper
• Pretarsal application of botulinum toxin for treatment of blepharospasm.

  1995cited by this paper
• Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria.

  1995cited by this paper
• The epidemiology of PSP.

  1994cited by this paper
• Clinical diagnosis and diagnostic criteria of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome).

  1994cited by this paper
• Initial experience with electroconvulsive therapy for progressive supranuclear palsy

  1994cited by this paper
• Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy

  1994cited by this paper
• Retrospective study of drug response in 87 patients with progressive supranuclear palsy.

  1993cited by this paper
• Idazoxan treatment in progressive supranuclear palsy

  1991cited by this paper
• Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations.

  1990cited by this paper
• Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy.

  1990cited by this paper
• Physostigmine treatment of progressive supranuclear palsy

  1989cited by this paper
• Failure of cholinergic agonist RS‐86 to improve cognition and movement in PSP despite effects on sleep

  1989cited by this paper
• Treatment of progressive supranuclear palsy with tricyclic antidepressants

  1985cited by this paper
• Methysergide in progressive supranuclear palsy

  1985cited by this paper
• Progressive supranuclear palsy: Clinical features and response to treatment in 16 patients

  1983cited by this paper
• Progressive supranuclear palsy

  1981cited by this paper
• Progressive supranuclear palsy: pneumoencephalography, electronystagmography and treatment with methysergide.

  1981cited by this paper
• The treatment of progressive supranuclear palsy with L-dopa.

  1973cited by this paper
• Observations on the efficacy of L-dopa in progressive supranuclear palsy.

  1971cited by this paper
• Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening

  year unknowncited by this paper

• Richardson Syndrome Variant of Progressive Supranuclear Palsy: A Case Report

  2025cites this paper
• Machine Learning-Based Differential Diagnosis of Parkinson’s Disease Using Kinematic Feature Extraction and Selection

  2025cites this paper
• Chorea and Levodopa-Induced Dyskinesia in Corticobasal Syndrome: Two Case Reports with Pathological Insights and Literature Review.

  2025cites this paper
• Diagnostic utility of biomarkers in progressive supranuclear palsy: toward a biotyping framework

  2025cites this paper
• Paralisi sopranucleare progressiva

  2024cites this paper
• Quality of life in patients with progressive supranuclear palsy: a review of literature and implications for practice

  2024influential citation
• Paralysie supranucléaire progressive

  2024cites this paper
• Quick computer aided differential diagnostics based on repetitive finger tapping in Parkinson's disease and atypical parkinsonisms.

  2023cites this paper
• Significance of clinical symptoms and red flags in early differential diagnosis of Parkinson’s disease and atypical Parkinsonian syndromes

  2023cites this paper
• Investigational therapeutics for the treatment of progressive supranuclear palsy

  2022cites this paper
• Autopallidotomy: From Colloquial Term to Scientific Theory

  2022cites this paper
• Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care

  2021cites this paper
• Progressive Supranuclear Palsy and Corticobasal Degeneration.

  2021cites this paper
• Is Levodopa Response a Valid Indicator of Parkinson's Disease?

  2020cites this paper
• Progressive supranuclear palsy: Advances in diagnosis and management.

  2020cites this paper
• Corticobasal Degeneration

  2020cites this paper
• Pharmacological interventions in corticobasal degeneration: a review

  2020cites this paper
• Progressive supranuclear palsy as differential diagnosis of Parkinson's disease in the elderly.

  2019cites this paper
• Corticobasal degeneration.

  2019cites this paper
• Dystonia in atypical parkinsonian disorders.

  2019cites this paper
• Physiopathologie des troubles de la marche et du contôle postural dans la paralysie supranucléaire progressive : étude comparative des formes de Steele-Richardson et caribéenne

  2019cites this paper
• Dyskinesia in multiple system atrophy and progressive supranuclear palsy

  2019influential citation
• Available and future treatments for atypical parkinsonism. A systematic review

  2018cites this paper
• Therapeutic options for Progressive Supranuclear Palsy including investigational drugs

  2017cites this paper
• Advances in the Clinical Differential Diagnosis of Parkinson's Disease.

  2017cites this paper
• Progressive supranuclear palsy (PSP): Richardson syndrome and other PSP variants

  2016influential citation
• Structural Imaging and Parkinson’s Disease: Moving Toward Quantitative Markers of Disease Progression

  2016cites this paper
• Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options

  2016cites this paper
• Possible Treatments of Atypical Parkinsonism

  2016cites this paper
• A Review of Treatment Options for Progressive Supranuclear Palsy

  2016cites this paper
• La paralysie supranucléaire progressive

  2015cites this paper
• Are there treatments for atypical parkinsonism? An update on actual options

  2015cites this paper
• Impact of Aspiration Pneumonia on the Clinical Course of Progressive Supranuclear Palsy: A Retrospective Cohort Study

  2015cites this paper
• Treatment options for atypical parkinsonisms

  2015cites this paper
• Clinical Trials: Past, Current, and Future for Atypical Parkinsonian Syndromes

  2014cites this paper
• Psychiatric issues in cognitive impairment

  2014cites this paper
• Long-term follow-up of deep brain stimulation of peduncolopontine nucleus in progressive supranuclear palsy: Report of three cases

  2014influential citation
• Treatment of progressive supranuclear palsy with autologous adipose tissue-derived mesenchymal stem cells: a case report

  2014cites this paper
• A case of atypical progressive supranuclear palsy

  2013cites this paper
• Cellular minigene models for the study of allelic expression of the tau gene and its role in progressive supranuclear palsy

  2013cites this paper
• Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients.

  2013cites this paper
• Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

  2012influential citation
• La paralysie supranucléaire progressive : nouveaux concepts cliniques et neuropathologiques

  2012cites this paper
• Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy

  2012influential citation
• Handbook of Atypical Parkinsonism: Corticobasal degeneration

  2011cites this paper
• Effectiveness of an Inpatient Movement Disorders Program for Patients with Atypical Parkinsonism

  2011cites this paper
• Progressive supranuclear palsy: new concepts.

  2010cites this paper
• Les troubles de la marche et de l’équilibre dans les syndromes parkinsoniens « plus »

  2010cites this paper
• [Gait and balance disorders in patients with atypical parkinsonian syndromes].

  2010cites this paper
• Clinical heterogeneity in progressive supranuclear palsy: Problems of clinical diagnostic criteria of NINDS‐SPSP in a retrospective study of seven Japanese autopsy cases

  2010cites this paper
• Repetitive transcranial magnetic stimulation in patients with progressive supranuclear palsy: a pilot study.

  2009cites this paper
• Diagnosis and Management of Progressive Supranuclear Palsy

  2009cites this paper
• Progressive Supranuclear Palsy: A Current Review

  2008cites this paper
• Current and future therapeutic approaches in progressive supranuclear palsy.

  2008cites this paper
• La dégénérescence corticobasale : une affection rare et méconnue

  2008cites this paper
• Progressive supranuclear palsy and corticobasal degeneration: similarities and differences

  2008cites this paper
• Corticobasal degeneration.

  2007cites this paper
• Levodopa responsiveness in disorders with parkinsonism: A review of the literature

  2007cites this paper
• The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study

  2007cites this paper
• Treatment of Dementia in Parkinsonian Syndromes with Cholinesterase Inhibitors

  2007cites this paper
• Current and future treatments in progressive supranuclear palsy

  2006cites this paper
• International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study

  2006cites this paper
• Clinical Interventions in Aging Dovepress a Case of Atypical Progressive Supranuclear Palsy

  year unknowncites this paper